8-K: Rezolute Completes Enrollment in Phase 3 upLIFT Study

Rezolute, Inc. announced the full enrollment of its Phase 3 upLIFT study for ersodetug in tumor hyperinsulinism, with topline results anticipated mid-December 2026.

Summary

• Rezolute, Inc. has completed enrollment for its Phase 3 upLIFT study, investigating ersodetug for tumor hyperinsulinism (HI).
• The study, which is single-arm and open-label, includes 16 participants with insulinoma or non-islet cell tumors causing uncontrolled hypoglycemia.
• Topline data from the upLIFT study are expected in mid-December 2026.
• Previously, 7 out of 8 participants in the first half of the study met the responder criterion for the primary endpoint, achieving at least a 50% reduction in glucose infusion rate (GIR) and complete discontinuation of intravenous glucose.
• Ersodetug has been well-tolerated with no reported drug-related safety findings.
• The company plans to continue its expanded access program for compassionate use of ersodetug.
• Rezolute is also advancing a path for congenital hyperinsulinism and anticipates potential advancement of both indications in 2027 if study outcomes are favorable.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, indicating progress in a critical clinical trial for an ultra-rare disease, though topline results are still pending.

Positives

• Full enrollment in the Phase 3 upLIFT study has been achieved, marking a significant milestone.
• 7 out of 8 participants in the initial half of the study met the primary endpoint criteria, including complete discontinuation of intravenous glucose.
• Ersodetug has demonstrated a good safety profile, with no drug-related safety findings reported to date.
• The company has a clear timeline for topline data release, expected mid-December 2026.
• Potential to advance both tumor HI and congenital HI indications in 2027, contingent on favorable study outcomes.

Negatives

• One participant in the first half of the study was considered a non-responder due to electing hospice care and subsequent death from cancer progression.
• The primary endpoint requires a response rate of at least 56% for statistical significance, with a lower bound of the 95% confidence interval of 30%.

Risks

• Actual results may differ materially from anticipated results due to the inherent uncertainty in predicting outcomes.
• There can be no assurance that regulatory authorities will approve ersodetug, even if study results meet endpoints.
• Factors discussed in Rezolute's SEC filings, including Risk Factors in its 10-K and 10-Q reports, could impact future results.

Future Outlook

Topline data from the upLIFT study are expected mid-December 2026. If the study outcomes are favorable, the company anticipates the potential to advance both tumor hyperinsulinism and congenital hyperinsulinism indications in 2027.

Management Comments

• Completing enrollment in the upLIFT study marks an important milestone as we advance a potentially transformative treatment option for patients living with tumor hyperinsulinism.
• Now that we have a path forward for congenital hyperinsulinism, we look forward to announcing topline data from upLIFT and to the extent the study outcomes are favorable, the potential to advance both indications in 2027.
• We are deeply grateful to the patients, families, investigators and advocacy groups whose dedication and partnership have enabled us to reach this point.

Industry Context

StockSavvy.ai notes that Rezolute is operating in the ultra-rare disease space, specifically targeting refractory hypoglycemia. The successful enrollment in a Phase 3 study for a condition with significant unmet need is a positive step, aligning with industry trends towards specialized therapeutics for niche patient populations.

Stakeholder Impact

• Patients with tumor hyperinsulinism may benefit from a potentially transformative treatment option.
• Shareholders may see increased confidence in the company's progress, pending topline results.
• Advocacy groups and investigators are acknowledged for their contributions to reaching this milestone.

Next Steps

• Announce topline data from the upLIFT study (expected mid-December 2026).
• Continue expanded access program for compassionate use of ersodetug.
• Potentially advance both tumor HI and congenital HI indications in 2027, contingent on favorable study outcomes.

Key Dates

Recommendation

The completion of enrollment is a positive operational milestone, and early data from the first half of the study are encouraging. However, the critical topline results are still pending, and regulatory approval is not guaranteed. Therefore, a 'hold' position is prudent until more definitive data are available.

Keywords

hyperinsulinism, hypoglycemia, ersodetug, clinical trial, tumor, enrollment, oncology, rare disease